FDA And Allergan Resume Promotional Battle After Settling First Amendment Suit
DDMAC letter objects to direct mail piece implying Lumigan is superior to Xalatan in lowering intraocular pressure. FDA had cited Allergan for similar claims in 2005.
DDMAC letter objects to direct mail piece implying Lumigan is superior to Xalatan in lowering intraocular pressure. FDA had cited Allergan for similar claims in 2005.